SapVax

SapVax is a biotechnology company developing a novel class of fully synthetic cancer vaccines based on its proprietary self-adjuvanting peptide (SAP) platform. The technology, licensed from Yale University, enables the creation of chemically defined vaccines that combine tumor-specific antigens with potent adjuvants in a single molecule. This approach is designed to stimulate robust T-cell mediated immune responses while simplifying manufacturing compared to traditional vaccine technologies. The company's lead program, SVX-001, is a therapeutic vaccine targeting HPV-positive malignancies such as head and neck and cervical cancers. SapVax is backed by BioMotiv and aims to address significant unmet needs in the immuno-oncology space.